38 results about "Feline coronavirus" patented technology

Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1′-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.

Provided is a method for treatment and / or prophylaxis of FIP (feline infectious peritonitis) in cats. The method is performed by administering to a cat a composition comprising a therapeutic and / or prophylactic amount of a cysteine protease inhibitor. The cysteine protease inhibitor can be a selective cathepsin B inhibitor. Also provided is a method for inhibiting FIPV (Feline infectious peritonitis virus) replication. The method comprises contacting a cell infected with FIPV with a cysteine protease inhibitor in an amount effective to inhibit replication of FIPV. It is expected the method will be effective for therapy or prophylaxis of FIP in any species of cat and will be effective against any strain of feline coronavirus.

Provided is a method for determining whether a feline is infected with pathogenic Feline Infectious Peritonitis Virus (FIPV) or Feline Enteric Infection Virus (FECV). The method involves determining the presence or absence of intact or mutated S1 / S2 and S2′ cleavage sites in the spike protein of serotype 1 feline coronaviruses (FCoV1). The presence of both intact cleavage sites is indicative of FECV. The presence of a mutation in one or both cleavage sites is indicative of FIPV. The absence of both sites is indicative of an absence of FCoV1 infection. Compositions for use in determining infection and kits are also provided.

The invention discloses a feline coronavirus recombinant antigen, its genetic engineering subunit vaccine and application thereof. The feline coronavirus recombinant antigen includes a recombinant protein having the sequence shown in SEQ ID NO: 2 or its added or truncated sequence. The vaccine comprises the recombinant protein and a pharmaceutically acceptable carrier. The feline coronavirus recombinant antigen provided by the invention has high immunogenicity, can produce high-concentration neutralizing antibodies, and will not produce ADE effect. At the same time, the present invention expresses the feline coronavirus recombinant antigen by adopting the baculovirus insect cell expression system and using the method of suspension culture Sf9 cells, not only the expression level is high, the protein immunogenicity is good, but also the vaccine prepared thereby It also has the advantages of easy quality control, batch-to-batch stability, and low production cost.

The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.

The invention discloses an integrated nucleic acid detection cartridge for feline coronavirus, comprising a box body, wherein a lysis chamber, a first cleaning chamber and a second cleaning chamber are sequentially arranged in the box body from top to bottom, wherein the lysis chamber is connected to the box cover, The second cleaning chamber is connected to the reaction chamber provided at the bottom of the outer side of the box body; the two connected sections of the cracking chamber, the first cleaning chamber, the second cleaning chamber and the reaction chamber are respectively provided with columns with the direction of the plunger holes perpendicular to the connection direction The plug, the plunger hole of the plunger is provided with a hydrophobic liquid sealing material; the reaction chamber is provided with an amplification reaction solution, and the amplification reaction solution includes a primer-probe mixture of the feline coronavirus ORF gene; the reaction chamber A fusible material layer is arranged in the middle, and a DNA polymerase solution is embedded in the soluble material layer. The present invention can rapidly and integrally carry out PCR amplification and detection of feline coronavirus under the condition of relatively low cost, and solve the problems of poor repeatability of the current technology, time-consuming detection method, complicated operation and the like.

The invention discloses use of conivaptan hydrochloride in the preparation of a drug for treating feline infectious peritonitis. Conivaptan hydrochloride has very low toxicity to feline normal cells and has an obvious inhibition effect to feline coronavirus and is capable of obviously reducing virulence of viruses in the cells; an indirect immunofluorescence detection result shows that conivaptanhydrochloride can effectively inhibit the proliferation of the feline coronavirus in the cells and has dose dependence. Therefore, conivaptan hydrochloride can be used for preparing a feline coronavirus inhibitor for treating feline infectious peritonitis and has the advantages of good treatment effect, high safety and the like.